Auvray Marie, Benderra Marc-Antoine, Bretagne Marie, Faouzi Sara, Lebellec Loïc, Majhoubi Linda, Saint-Ghislain Mathilde, Vignot Stéphane
Association pour l'enseignement et la recherche des internes en oncologie (AERIO), 149, avenue du Maine, 75014 Paris, France.
Association pour l'enseignement et la recherche des internes en oncologie (AERIO), 149, avenue du Maine, 75014 Paris, France.
Bull Cancer. 2017 Sep;104(9):744-751. doi: 10.1016/j.bulcan.2017.06.010. Epub 2017 Aug 18.
Since the advent of the HER2 biomarker allowing access to treatment with trastuzumab, we observe an explosion in research for biomarkers, in which the economic pressure linked to the costs of developing new products must not be overlooked, in order to better select the molecules to be developed and the patients who can benefit from them. Personalized medicine takes a little more space each year in the overall care of our patients and the search for specific indicators, has become unavoidable. Rapid identification of oncogenic changes, their therapeutic targeting and the anticipation of resistance or toxicity mechanisms is a challenge. From blood markers, proteins to tumor genomic profiling and new markers in medical imaging, clinicians, researchers, and patients all are looking for the Holy Grail. This article synthetizes oncology resident's reflexions during the ESMO congress which took place in Copenhagen from 7 to 11 October 2016. The aim was to select the most relevant or promising results for future clinical practice.
自HER2生物标志物问世，使得曲妥珠单抗得以应用于治疗以来，我们观察到生物标志物研究呈爆发式增长，其中与新产品研发成本相关的经济压力不容忽视，以便更好地筛选待研发的分子以及能从中获益的患者。个性化医疗在我们对患者的整体护理中所占比重逐年增加，寻找特定指标已成为必然。快速识别致癌性变化、对其进行治疗靶向以及预测耐药或毒性机制是一项挑战。从血液标志物、蛋白质到肿瘤基因组分析以及医学影像中的新标志物，临床医生、研究人员和患者都在寻找圣杯。本文总结了2016年10月7日至11日在哥本哈根举行的欧洲肿瘤内科学会（ESMO）大会期间肿瘤学住院医师的思考。目的是为未来的临床实践挑选最相关或最有前景的结果。
